Eikon announced itself in 2021 with former Merck & Co. exec Roger Perlmutter, M.D., Ph.D., at the helm and quickly ...

Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody ...

Agomab Therapeutics and SpyGlass Pharma secured a combined $350 million in two separate initial public offerings on Thursday ...

Forgent, Eikon, and Bob’s Discount Furniture are making their debut in a mixed market for IPOs. SpaceX and other AI stocks ...

With an oversubscribed trading debut now in the books, Veradermics—developing an oral version of the molecule behind ...

The offering is one of four biotech IPOs that could price by Friday, and comes during the busiest week for such activity ...

Unprofitable biotech Veradermics, which still needs FDA approval for its hair loss pill, surged on its debut day.

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to ...

The biotech, which raised more than $800 million privately on the promise of artificial intelligence-aided drug discovery, is ...

Eikon Therapuetics increased the size of its initial public offering at the last minute and priced at the top of its range, ...

Biotech firm Eikon Therapeutics raises $381M in an oversubscribed IPO. The cancer & neurology drugmaker is the third successful biotech offering of 2026.